CI 21100 is classed chemically as a disazo colour.
定义
美国FDA 物质登记 · UNII O8RYS681QI · 登记名称 PIGMENT YELLOW 13 · 单一化学物质
CI 21100 is classed chemically as a disazo colour. It conforms to the formula:
化妆品中的作用
染发HAIR DYEING着色COLORANT
安全与法规参考
- 禁用
- 阿根廷 · 巴西 · 东盟 · 欧盟 · 英国
- 限用·禁用
- 阿根廷 · 巴西 · 东盟 · 欧盟 · 中国
- 准用着色剂
- 东盟
来源: 东盟化妆品指令 · 欧盟化妆品法规 · 韩国食药处 化妆品法规信息 · 英国化妆品法规 · 台湾FDA 化妆品成分
台湾
- 2. 未列載於此表規定範圍之成分，於歐盟、美國及日本三國家地區，任何其中一個國家地區官方已公告（以生效日為準）其使用基準者，得參照其基準規定准予使用(但下表CI 11380 等十九項成分不適用)，惟於申請查驗登記時，應同時檢附該等地區之准許使用基準證明文件。
- 用途 : 色素
- 最大配合量 : 不得使用於染髮用途化粧品。
来源: 韩国食药处 化妆品法规信息
未列入韩国有毒物质 GHS 分类 · 现有化学物质
欧盟化妆品法规 附录IV（准用着色剂） 第47项 · 最高浓度 Rinse-off products
来源: 欧盟准用着色剂（附录IV）
欧盟化妆品法规 附录II（禁用物质） 第1351项
来源: 欧盟禁用成分（附录II）
Restriction II/1351 (Pigment Yellow 13; CI 21100: when used as a substance in hair dye products)
来源: 欧盟 CosIng 成分清单
Restriction IV/47 (CI 21100) II/1351 (Pigment Yellow 13; CI 21100: when used as a substance in hair dye products)
来源: 欧盟 CosIng 成分清单
详细资料——标示名称、识别编号、物性、试验记录、文献
别名和识别信息
CI 21100INCI피그먼트황색13호韩国标示名称（食药处标准名）Butanamide, 2,2'-[[3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl]bis(azo)]bis[N-(2,4-dimethylphenyl)-3-oxo-同义名PIGMENT YELLOW 13同义名
- CAS No.化学物质登记号
- 5102-83-0
- EC No.欧盟化学品目录编号
- 225-822-9
- DTXSID美国EPA化学品编号
- DTXSID0029268
- DTXCID美国EPA化合物编号
- DTXCID30809902
- IUPAC
- 2,2'-[(3,3'-Dichloro[1,1'-biphenyl]-4,4'-diyl)di(hydrazin-2-yl-1-ylidene)]bis[N-(2,4-dimethylphenyl)-3-oxobutanamide]
- 分子式
- C36H34Cl2N6O4
- 分子量
- 685.61 g/mol
实测物性
- 性状
- 固体
- 气味
- 无臭
- 初沸点和沸程
- 320 ℃
- 闪点
- 500 ℃
- 蒸气压
- (4.62E-023mmHg 25℃(估算值))
- 蒸气密度
- 23.7
- 比重
- 1.2
- 正辛醇/水分配系数（Kow）
- (&, gt, 6)
- 自燃温度
- (&, gt, 100℃)
- 分子量
- 685.598960
这是对物质本身测得的数值。韩国安全保健公团（KOSHA）的资料仅供编写和审核安全数据表参考，并非原料商品的规格。
来源: 韩国安全保健公团 安全数据表
产品实际使用的用途
刺激与致敏试验记录
记录有皮肤试验 8 项、眼部试验 7 项。
归类为低15 项
试验结论基本一致（100%）。 这是对原料本身的试验记录，与成品中所含浓度下的刺激性不同。
查看全部 15 项试验
- Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation) according to EU Method B.6 (Skin Sensitisation) - Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · equivalent or similar to OECD Guideline 406 (Skin Sensitisation) - Not likely to be sensitizing
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: method given in the "Hazardous Substances Regulations" under the U.S. Federal Hazardous Substances Labelling Act Sect. 191.11 (February 1965) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: described in the "Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics" (1959) of the US Association of Food and Drug Officials (AFDO). according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: FDA-guidelines according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: FDA guideline (Fed. Reg. Vol. 37, No. 38, 1972) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) according to EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: described in the "Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics" (1959) of the US Association of Food and Drug Officials (AFDO) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: FDA guideline (Fed. Reg., Vol. 37, No. 38, 1972) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: procedure set out in the "Hazardous Substances Regulations" under the U.S.A. Federal Hazardous Substances Labelling Act Sect. 191.12 (February 1965), conducted with slight modification. according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: described in the "Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics" (1959) of the US Association of Food and Drug Officials (AFDO) according to
来源: 美国EPA CompTox